Fundraising Fox
Werewolf Therapeutics
Watertown, US · Founded 2017 · Delaware corporation · 6 known investors
Find your way into Werewolf Therapeutics
Sign up to see every warm intro you have to Werewolf Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Werewolf Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.
Founders & leadership
Werewolf Therapeutics was founded in 2017 by Daniel J. Hicklin and Luke Evnin.
Board
Investors · 6
How we know: DC Investment Partners's portfolio page · Not right? Tell us
How we know: K2 HealthVentures's portfolio page · Not right? Tell us
How we know: Longwood Fund's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: MPM BioImpact's portfolio page · a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$128.2M disclosed across 2 rounds · 2019–2020
▶$72.1MraisedJan 2021 · 19 investors · PharmaceuticalsRule 506(b)
- Luke EvninDirector
- Briggs MorrisonDirector
- Daniel HicklinExecutive Officer, Director
- Sakae AsanumaDirector
- Alon LazarusDirector
- Elise WangDirector
- David CordoExecutive Officer
- Derek DiRoccoDirector
- Offering amount
- $72.1M
- Amount sold
- $72.1M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$56.2MraisedAug 2020 · 10 investors · PharmaceuticalsRule 506(b)
- Luke EvninDirector
- Daniel HicklinExecutive Officer, Director
- Alon LazarusDirector
- David CordoExecutive Officer
- Christoph WestphalDirector
- Briggs MorrisonDirector
- Sakae AsanumaDirector
- Offering amount
- $56.2M
- Amount sold
- $56.2M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Werewolf Therapeutics went on to found or lead other companies.
Related companies · 6
Companies working in the same space as Werewolf Therapeutics.
Acquisitions · 1
Early investors' stakes continue via these dealsAmbros Therapeutics is a clinical-stage biotechnology company developing medicines for diseases with high unmet medical need, with a lead program targeting complex regional pain syndrome type 1 (CRPS-1), a rare condition typically following limb injury. Its investigational treatment is neridronate, a bisphosphonate, being evaluated in a Phase 3 pivotal trial (CRPS-RISE).
Frequently asked questions
- What does Werewolf Therapeutics do?
- Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.
- Who founded Werewolf Therapeutics?
- Werewolf Therapeutics was founded by Daniel J. Hicklin, Luke Evnin in 2017.
- Who are Werewolf Therapeutics's investors?
- Werewolf Therapeutics's investors include DC Investment Partners, K2 HealthVentures, Longwood Fund, MPM BioImpact, RA Capital, Taiho Ventures, LLC.
- How much funding has Werewolf Therapeutics raised?
- Werewolf Therapeutics has disclosed $128.2M raised across 2 rounds.
- Where is Werewolf Therapeutics headquartered?
- Werewolf Therapeutics is headquartered in Watertown, US.